NCT03070717 (HELP) is a clinical trial of Observation & Diagnosis in Pathologic Myopia, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT03070717?

NCT03070717 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT03070717?

Interventions in NCT03070717: Observation & Diagnosis.

What condition does NCT03070717 study?

NCT03070717 studies Pathologic Myopia.

Is NCT03070717 still recruiting?

NCT03070717 is currently completed. Last updated 19 July 2019.

Last reviewed 2019-07-19 · How we verify

NCT03070717: HELP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)

Completed Last updated 19 July 2019

What this trial tests

trial testing Observation & Diagnosis in Pathologic Myopia in 153 participants. Completed in 23 May 2019.

Timeline

12 June 2014

Primary endpoint
23 May 2019

23 May 2019

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	Completed
Study type	OBSERVATIONAL
Enrollment	153
Start date	12 June 2014
Primary completion	23 May 2019
Estimated completion	23 May 2019
Sites	26 locations across Germany

Drugs / interventions tested

Observation & Diagnosis

Conditions studied

Pathologic Myopia — all drugs for Pathologic Myopia →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Pathologic Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research project intends to observe patients with high myopia who show pathological retinal changes, in order to evaluate more data on the risk factors for developing mCNV within this research project population in Germany.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pathologic Myopia

Currently open trials in the same condition.

NCT07312214 — LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia · NA · recruiting
NCT06322433 — Follow up of High Myopic Eyes · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03070717 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 19 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03070717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing